|
GB1468172A
(en)
*
|
1973-03-28 |
1977-03-23 |
Benzon As Alfred |
Oral drug preparations
|
|
DE2336218C3
(de)
*
|
1973-07-17 |
1985-11-14 |
Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz |
Orale Arzneiform
|
|
DE2343218C2
(de)
*
|
1973-08-28 |
1986-08-07 |
Hoechst Ag, 6230 Frankfurt |
Furosemid enthaltende Pellets
|
|
FR2377196A1
(fr)
*
|
1977-01-13 |
1978-08-11 |
Lipha |
Composition medicamenteuse a usage oral
|
|
GB1561204A
(en)
*
|
1977-06-01 |
1980-02-13 |
Ici Ltd |
Sustained release pharmaceutical composition
|
|
FR2397840B1
(fr)
*
|
1977-07-22 |
1981-03-20 |
Cherqui Jean |
|
|
US4153677A
(en)
*
|
1978-05-18 |
1979-05-08 |
Sterling Drug Inc. |
Controlled-release composition
|
|
GB1584130A
(en)
*
|
1978-05-30 |
1981-02-04 |
Wyeth John & Brother Ltd |
Indole derivatives
|
|
DD146547A5
(de)
*
|
1978-07-15 |
1981-02-18 |
Boehringer Sohn Ingelheim |
Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
|
|
SE426548B
(sv)
*
|
1978-12-05 |
1983-01-31 |
Haessle Ab |
Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
|
|
US4173626A
(en)
*
|
1978-12-11 |
1979-11-06 |
Merck & Co., Inc. |
Sustained release indomethacin
|
|
SE7813246L
(sv)
*
|
1978-12-22 |
1980-06-23 |
Haessle Ab |
Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
|
|
JPS55129219A
(en)
*
|
1979-03-29 |
1980-10-06 |
Asahi Chem Ind Co Ltd |
Slow-releasing preparation
|
|
FR2454804B1
(fr)
*
|
1979-04-26 |
1986-11-21 |
Sanofi Sa |
Medicament a base de dihydroergotoxine et son procede de preparation
|
|
US4252786A
(en)
*
|
1979-11-16 |
1981-02-24 |
E. R. Squibb & Sons, Inc. |
Controlled release tablet
|
|
US4543370A
(en)
*
|
1979-11-29 |
1985-09-24 |
Colorcon, Inc. |
Dry edible film coating composition, method and coating form
|
|
FR2470599A1
(fr)
*
|
1979-12-07 |
1981-06-12 |
Panoz Donald |
Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
|
|
DE3000979A1
(de)
*
|
1980-01-12 |
1981-07-23 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
|
|
SE8103843L
(sv)
*
|
1981-06-18 |
1982-12-19 |
Astra Laekemedel Ab |
Farmaceutisk mixtur
|
|
DE3126703A1
(de)
|
1981-07-07 |
1983-01-27 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Bromhexin-retardform und verfahren zu ihrer herstellung
|
|
US4587118A
(en)
*
|
1981-07-15 |
1986-05-06 |
Key Pharmaceuticals, Inc. |
Dry sustained release theophylline oral formulation
|
|
DE3278491D1
(en)
*
|
1981-07-15 |
1988-06-23 |
Key Pharma |
Sustained release theophyline
|
|
US4415547A
(en)
*
|
1982-06-14 |
1983-11-15 |
Sterling Drug Inc. |
Sustained-release pharmaceutical tablet and process for preparation thereof
|
|
EP0111560A4
(fr)
*
|
1982-06-14 |
1987-02-03 |
Key Pharma |
Aspirine a liberation entretenue.
|
|
US4508702A
(en)
*
|
1982-06-14 |
1985-04-02 |
Key Pharmaceuticals, Inc. |
Sustained release aspirin
|
|
US4557925A
(en)
*
|
1982-07-08 |
1985-12-10 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
|
WO1984000295A1
(fr)
*
|
1982-07-09 |
1984-02-02 |
Key Pharma |
Forme de dosage de quinidine a liberation entretenue
|
|
US4634587A
(en)
*
|
1982-07-09 |
1987-01-06 |
Key Pharmaceuticals, Inc. |
Sustained release quinidine dosage form
|
|
IE55745B1
(en)
*
|
1983-04-06 |
1991-01-02 |
Elan Corp Plc |
Sustained absorption pharmaceutical composition
|
|
USRE33994E
(en)
*
|
1983-08-16 |
1992-07-14 |
Burroughs Wellcome Co. |
Pharmaceutical delivery system
|
|
GB8322007D0
(en)
*
|
1983-08-16 |
1983-09-21 |
Wellcome Found |
Pharmaceutical delivery system
|
|
JPS6051106A
(ja)
*
|
1983-08-31 |
1985-03-22 |
Yamanouchi Pharmaceut Co Ltd |
塩酸アモスラロ−ル持続性製剤
|
|
US4749575A
(en)
*
|
1983-10-03 |
1988-06-07 |
Bio-Dar Ltd. |
Microencapsulated medicament in sweet matrix
|
|
US4555399A
(en)
*
|
1983-11-18 |
1985-11-26 |
Key Pharmaceuticals, Inc. |
Aspirin tablet
|
|
DE3403329A1
(de)
*
|
1984-02-01 |
1985-08-01 |
Horst Dr. 4019 Monheim Zerbe |
Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
|
|
GB2159714B
(en)
*
|
1984-06-04 |
1988-05-05 |
Sterwin Ag |
Pharmaceutical composition of sparingly soluble medicament and method for its preparation
|
|
GB8414221D0
(en)
*
|
1984-06-04 |
1984-07-11 |
Sterwin Ag |
Unit dosage form
|
|
US4769027A
(en)
*
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
|
DE3485618D1
(de)
*
|
1984-08-17 |
1992-04-30 |
Wellcome Found |
Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und ihre herstellung.
|
|
US4629619A
(en)
*
|
1984-09-05 |
1986-12-16 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
|
US4629620A
(en)
*
|
1984-09-05 |
1986-12-16 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
|
IE58110B1
(en)
*
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US4867984A
(en)
*
|
1984-11-06 |
1989-09-19 |
Nagin K. Patel |
Drug in bead form and process for preparing same
|
|
CA1268710A
(fr)
*
|
1984-11-06 |
1990-05-08 |
Nagin K. Patel |
Medicament sous forme de perles et procede de preparation
|
|
US4728512A
(en)
*
|
1985-05-06 |
1988-03-01 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US4666704A
(en)
*
|
1985-05-24 |
1987-05-19 |
International Minerals & Chemical Corp. |
Controlled release delivery system for macromolecules
|
|
US4904476A
(en)
*
|
1986-03-04 |
1990-02-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US4794001A
(en)
*
|
1986-03-04 |
1988-12-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US5286494A
(en)
*
|
1986-07-02 |
1994-02-15 |
Schering Aktiengesellschaft |
Medicinal agents with sustained action
|
|
JPS6327424A
(ja)
*
|
1986-07-17 |
1988-02-05 |
Shionogi & Co Ltd |
徐放性製剤およびその製造法
|
|
US4752470A
(en)
*
|
1986-11-24 |
1988-06-21 |
Mehta Atul M |
Controlled release indomethacin
|
|
US4786509A
(en)
*
|
1987-05-18 |
1988-11-22 |
Schering Corporation |
Dry sustained release theophylline oral formulation
|
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
US5122384A
(en)
*
|
1989-05-05 |
1992-06-16 |
Kv Pharmaceutical Company |
Oral once-per-day organic nitrate formulation which does not induce tolerance
|
|
US5084287A
(en)
*
|
1990-03-15 |
1992-01-28 |
Warner-Lambert Company |
Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
|
|
US6638963B1
(en)
|
1990-12-04 |
2003-10-28 |
Oregon Health And Science University |
Methods for treating circadian rhythm disorders
|
|
US5707652A
(en)
*
|
1990-12-04 |
1998-01-13 |
State Of Oregon |
Methods of treating circadian rhythm phase disorders
|
|
US5252337A
(en)
*
|
1991-06-25 |
1993-10-12 |
Eurand America, Inc. |
Controlled release calcium channel blocker microcapsules
|
|
IL110035A0
(en)
*
|
1994-06-16 |
1994-10-07 |
Tapuach Natural Technologies 1 |
Homeopathic formulations
|
|
US5744164A
(en)
*
|
1994-12-16 |
1998-04-28 |
Nestec S.A. |
Sustained release microparticulate caffeine formulation
|
|
US5834024A
(en)
*
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
|
US6270795B1
(en)
|
1995-11-09 |
2001-08-07 |
Microbiological Research Authority |
Method of making microencapsulated DNA for vaccination and gene therapy
|
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
|
FR2766367B1
(fr)
*
|
1997-07-22 |
2000-03-31 |
Plantes Et Medecines |
Granules homeopathiques et procede de fabrication
|
|
DE19732903A1
(de)
|
1997-07-30 |
1999-02-04 |
Falk Pharma Gmbh |
Pellet-Formulierung zur Behandlung des Intestinaltraktes
|
|
UA69413C2
(uk)
*
|
1998-05-22 |
2004-09-15 |
Брістол-Майерс Сквібб Компані |
Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
|
|
UA73092C2
(uk)
|
1998-07-17 |
2005-06-15 |
Брістол-Майерс Сквібб Компані |
Таблетка з ентеросолюбільним покриттям і спосіб її приготування
|
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
|
US20050037086A1
(en)
*
|
1999-11-19 |
2005-02-17 |
Zycos Inc., A Delaware Corporation |
Continuous-flow method for preparing microparticles
|
|
US20040185099A1
(en)
*
|
2000-01-20 |
2004-09-23 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
|
US6254888B1
(en)
*
|
2000-01-28 |
2001-07-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for coating pharmaceutical dosage forms
|
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
US6635277B2
(en)
|
2000-04-12 |
2003-10-21 |
Wockhardt Limited |
Composition for pulsatile delivery of diltiazem and process of manufacture
|
|
AU6815901A
(en)
*
|
2000-06-02 |
2001-12-17 |
Zycos Inc |
Delivery systems for bioactive agents
|
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
BR0115585A
(pt)
|
2000-11-28 |
2005-12-13 |
Fmc Corp |
Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
|
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
|
US20040234602A1
(en)
|
2001-09-21 |
2004-11-25 |
Gina Fischer |
Polymer release system
|
|
EP1429744A1
(fr)
*
|
2001-09-21 |
2004-06-23 |
Egalet A/S |
Systeme a liberation de polymere de morphine
|
|
US20040005358A1
(en)
*
|
2002-04-23 |
2004-01-08 |
Slugg Peter H. |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
|
US20040029959A1
(en)
*
|
2002-08-08 |
2004-02-12 |
John Devane |
Isosorbide mononitrate compositions and methods of their use
|
|
WO2004084868A1
(fr)
|
2003-03-26 |
2004-10-07 |
Egalet A/S |
Systeme de liberation regulee de morphine
|
|
CA2611081C
(fr)
*
|
2005-06-03 |
2016-05-31 |
Egalet A/S |
Systeme d'administration de medicaments permettant d'administrer des substances actives dispersees dans un milieu de dispersion
|
|
PT1919458E
(pt)
|
2006-01-27 |
2012-08-23 |
Univ California |
Cisteamina revestida entericamente, cisteamina e seus derivados
|
|
NZ577560A
(en)
*
|
2007-01-16 |
2012-01-12 |
Egalet Ltd |
Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
|
|
EP2155167A2
(fr)
|
2007-06-04 |
2010-02-24 |
Egalet A/S |
Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
|
|
MX2010011209A
(es)
|
2008-04-24 |
2010-11-12 |
Squibb Bristol Myers Co |
Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
|
|
NZ594207A
(en)
|
2009-02-06 |
2013-03-28 |
Egalet Ltd |
Immediate release composition resistant to abuse by intake of alcohol
|
|
NZ597283A
(en)
|
2009-06-24 |
2013-07-26 |
Egalet Ltd |
Controlled release formulations
|
|
ES2555927T3
(es)
|
2011-01-20 |
2016-01-11 |
Bionevia Pharmaceuticals Inc. |
Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
|
|
RU2638807C2
(ru)
|
2011-11-22 |
2017-12-15 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Способы и композиции для лечения воспаления и ишемического поражения
|
|
WO2013191965A1
(fr)
|
2012-06-18 |
2013-12-27 |
Principia Biopharma Inc. |
Pyrrolopyrimidines ou pyrazolopyrimidines covalentes réversibles utiles pour le traitement du cancer et de maladies auto-immunes
|
|
US20150140085A1
(en)
|
2012-06-29 |
2015-05-21 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
BR112015000150A2
(pt)
|
2012-07-06 |
2017-06-27 |
Egalet Ltd |
composições farmacêuticas dissuasoras de abuso de liberação controlada
|
|
TWI649100B
(zh)
|
2013-06-17 |
2019-02-01 |
地平線罕見醫學製藥有限責任公司 |
延遲釋放型半胱胺珠粒調配物,以及其製備及使用方法
|
|
PT3236953T
(pt)
|
2014-12-24 |
2021-01-29 |
Principia Biopharma Inc |
Dosagem específica de sítio de um inibidor de btk
|
|
UA124090C2
(uk)
|
2015-06-03 |
2021-07-21 |
Прінсіпіа Байофарма Інк. |
Інгібітори тирозинкінази
|
|
WO2016210165A1
(fr)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Inhibiteurs de la tyrosine kinase
|
|
EP3316877B1
(fr)
|
2015-07-02 |
2019-10-30 |
Horizon Orphan LLC |
Analogues de la cystéamine résistant à l'ado et utilisations de ceux-ci
|
|
US10143665B2
(en)
|
2015-11-17 |
2018-12-04 |
Horizon Orphan Llc |
Methods for storing cysteamine formulations and related methods of treatment
|
|
PE20181521A1
(es)
*
|
2015-12-08 |
2018-09-24 |
Ardea Biosciences Inc |
Composicion farmaceutica que comprende un potente inhibidor de urat1
|
|
CN115054586B
(zh)
|
2016-06-29 |
2024-08-02 |
普林斯匹亚生物制药公司 |
改性的释放制剂
|
|
BR112022014058A2
(pt)
|
2020-01-20 |
2022-09-13 |
Genzyme Corp |
Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
|
|
TW202203934A
(zh)
|
2020-04-17 |
2022-02-01 |
美商健臻公司 |
治療涉及全身過度發炎性反應的病症的受體相互作用蛋白激酶抑制劑
|
|
US20240124857A1
(en)
|
2021-02-19 |
2024-04-18 |
Dupont Nutrition Biosciences Aps |
Composition for gut health
|
|
BR112023015272A2
(pt)
|
2021-02-23 |
2023-11-07 |
Otsuka Pharma Co Ltd |
Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
|
|
CA3260159A1
(fr)
|
2022-06-30 |
2024-01-04 |
Principia Biopharma Inc. |
Inhibiteurs thérapeutiques de tyrosine kinase pour le traitement de la sclérose en plaques et de la myasthénie gravis
|
|
WO2024040043A1
(fr)
|
2022-08-16 |
2024-02-22 |
International N&H Denmark Aps |
Systèmes d'expression pour phosphatases
|
|
US20250375418A1
(en)
|
2022-09-02 |
2025-12-11 |
Otsuka Pharmaceutical Co., Ltd. |
1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder
|
|
US20260092088A1
(en)
|
2022-09-20 |
2026-04-02 |
International N&H Denmark Aps |
Variant anti-viral polypeptides
|
|
EP4601647A1
(fr)
|
2022-10-11 |
2025-08-20 |
Principia Biopharma Inc. |
Inhibiteurs thérapeutiques de tyrosine kinase contre la sclérose en plaques
|
|
WO2025064636A1
(fr)
|
2023-09-20 |
2025-03-27 |
Danisco Us Inc. |
Composition contenant une enzyme dégradant l'atp et ses utilisations
|
|
WO2025080755A1
(fr)
|
2023-10-13 |
2025-04-17 |
Nutrition & Biosciences USA 4, Inc. |
Procédés et compositions pour le vieillissement et la santé mitochondriale
|
|
WO2026050513A1
(fr)
|
2024-08-30 |
2026-03-05 |
Principia Biopharma Inc. |
Tolébrutinib contre la sclérose en plaques
|